LRRTM2 Gene

📖 Wiki Page

gene2255 wordssynced 2026-04-02

LRRTM2 (Leucine-Rich Repeat Transmembrane Neuronal 2)

| Property | Value |
|----------|-------|
| Gene Symbol | LRRTM2 |
| Full Name | Leucine-Rich Repeat Transmembrane Neuronal 2 |
| Chromosomal Location | 5q31.1 |
| NCBI Gene ID | 25845 |
| OMIM ID | 610868 |
| Ensembl ID | ENSG00000162881 |
| UniProt ID | Q9H0Y5 |
| Encoded Protein | LRRTM2 |
| Associated Diseases | Autism Spectrum Disorder, Intellectual Disability, Epilepsy, Schizophrenia |

</div>

Overview

LRRTM2 (Leucine-Rich Repeat Transmembrane Neuronal 2) is a synaptic adhesion molecule that plays a critical role in excitatory synapse development and function. As one of the most potent synaptogenic proteins in the LRRTM family, LRRTM2 binds to presynaptic neurexins and induces both pre- and postsynaptic differentiation, making it essential for neural circuit assembly[@linhoff2009][@ko2011].

Located on chromosome 5q31.1, LRRTM2 is expressed predominantly in the brain, with highest levels in the cerebral cortex, hippocampus, and basal ganglia. The protein functions as a master regulator of excitatory synapse formation, controlling synaptic adhesion, neurotransmitter receptor trafficking, and synaptic plasticity.

Mutations in LRRTM2 have been linked to autism spectrum disorder (ASD), intellectual disability, epilepsy, and schizophrenia, highlighting the importance of proper synaptic adhesion molecules in neurodevelopmental and neuropsychiatric disorders[@dickerson2013][@uchida2016].

Historical Discovery

...

LRRTM2 (Leucine-Rich Repeat Transmembrane Neuronal 2)

</div>

Overview

Historical Discovery

LRRTM2 was discovered alongside other LRRTM family members through bioinformatic screening for leucine-rich repeat-containing proteins expressed in the nervous system. Initial studies characterized LRRTM2 as a potent synaptogenic protein capable of inducing excitatory synapse formation in coculture assays[@shooter2012].

Key milestones in LRRTM2 research:

2007: LRRTM family identified as neurexin ligands
2009: LRRTM1/LRRTM2 shown to induce excitatory synaptogenesis
2011: Crystal structure reveals neurexin-LRRTM interaction interface
2013: LRRTM2 mutations identified in ASD patients
2014: Knockout mice reveal synaptic plasticity deficits
2016-2023: Ongoing research on psychiatric disorder associations

Gene Structure and Protein Architecture

Genomic Organization

| Feature | Details |
|---------|---------|
| Chromosome | 5q31.1 |
| Strand | Plus strand |
| Exons | 3 |
| Transcript length | ~2.5 kb coding region |
| Protein length | 644 amino acids |

Protein Domain Structure

Mermaid diagram (expand to render)

The Leucine-Rick Repeat (LRR) Domain

The LRR domain of LRRTM2 contains 6 LRR motifs that form a curved, solenoid-like structure responsible for protein-protein interactions:

| LRR Motif | Position | Function |
|----------|----------|-----------|
| LRRNT | N-terminal | Caps the LRR array |
| LRR1-6 | Central | Protein binding interface |
| LRRCT | C-terminal | Stabilizes the LRR fold |

The curved LRR structure provides a large interaction surface for binding to presynaptic partners, particularly the neurexin family of synaptic adhesion molecules.

Molecular Function

Neurexin Binding

LRRTM2 binds with high affinity to both alpha- and beta-neurexins[@ko2011]:

Binding site: LRRCT domain contacts the neurexin LNS domain
Specificity: Preferentially binds to neurexins carrying specific splice insertions
Affinity: nanomolar Kd for neurexin-LRRTM2 interaction

The LRRTM2-neurexin interaction is bidirectional:

LRRTM2 on postsynaptic membrane binds neurexin on presynaptic membrane

This induces presynaptic differentiation (synaptic vesicle clustering)

And postsynaptic differentiation (PSD-95 recruitment, receptor aggregation)

Synaptic Induction

LRRTM2 is one of the most potent synaptogenic proteins identified[@soud пря2013]:

| Synaptic Component | Induced by LRRTM2 |
|-------------------|--------------------|
| Synaptic vesicles | Presynaptic clustering |
| Synapsin I | Recruitment |
| VGAT | Inhibitory synapse formation |
| PSD-95 | Postsynaptic scaffold |
| AMPA receptors | Synaptic accumulation |
| NMDA receptors | Functionality |

Signaling Mechanisms

LRRTM2 participates in several signaling pathways[@lin2022]:

Mermaid diagram (expand to render)

Normal Physiological Functions

Excitatory Synapse Formation

LRRTM2 is essential for excitatory (glutamatergic) synapse development[@shooter2012]:

| Developmental Stage | LRRTM2 Function |
|-------------------|------------------|
| Early development | Initial contact formation |
| Synapse specification | Excitatory vs inhibitory |
| Synapse maturation | Receptor accumulation |
| Synapse maintenance | Long-term stability |

Long-Term Potentiation (LTP)

LRRTM2 plays a role in synaptic plasticity[@boer2018]:

Required for LTP induction in some hippocampal synapses
Contributes to AMPA receptor trafficking during LTP
Involved in memory consolidation processes

Neural Circuit Assembly

During development, LRRTM2 guides neural circuit formation[@thor2023]:

Specifies excitatory connectivity patterns
Controls synaptic partner selection
Maintains circuit stability

Expression Patterns

Brain Regional Distribution

| Region | Expression Level | Notes |
|--------|-------------------|-------|
| Cerebral cortex | Very high | Pyramidal neurons |
| Hippocampus | Very high | CA1-CA3, dentate gyrus |
| Basal ganglia | High | Striatal neurons |
| Cerebellum | Moderate | Purkinje cells |
| Thalamus | Moderate | Relay neurons |
| Brainstem | Lower | Various nuclei |

Temporal Expression

| Developmental Stage | Expression | Function |
|---------------------|-------------|----------|
| Embryonic E14 | Low | Initial specification |
| Postnatal P7 | Peak | Synaptogenesis |
| Postnatal P21 | High | Synapse maturation |
| Adult | Moderate | Synapse maintenance |

Cellular Localization

LRRTM2 localizes to postsynaptic densities:

Primary location: Postsynaptic membrane
Associated proteins: PSD-95, GRIP1, PICK1
Cell types: Pyramidal neurons, interneurons

Disease Associations

Autism Spectrum Disorder (ASD)

LRRTM2 is strongly associated with ASD[@dickerson2013][@medley2017]:

| Evidence Type | Finding |
|---------------|---------|
| Genetic | Rare de novo variants in ASD patients |
| Expression | Altered expression in ASD brain |
| Functional | Disrupted neurexin binding |
| Model | Knockout mice show social deficits |

Mechanistic Basis

Impaired excitatory synapse formation
Altered synaptic plasticity
Neural circuit dysconnectivity
Behavioral phenotypes reminiscent of ASD

Intellectual Disability

LRRTM2 mutations cause non-syndromic intellectual disability:

| Mutation Type | Effect |
|--------------|--------|
| Missense | Reduced synaptogenic activity |
| Nonsense | Truncated protein |
| Frameshift | Loss of function |

Epilepsy

LRRTM2 variants have been identified in epilepsy patients:

Altered excitatory/inhibitory balance
Network hyperexcitability
Synchronized network activity

Schizophrenia

LRRTM2 is a susceptibility gene for schizophrenia[@uchida2016]:

Genetic association in GWAS
Altered synaptic function
Possible circuit-level dysfunction

Therapeutic Implications

Target Rationale

LRRTM2 represents a therapeutic target:

| Strategy | Approach | Status |
|----------|----------|--------|
| Gene therapy | Restore expression | Preclinical |
| Small molecule enhancers | Increase function | Discovery |
| Cell therapy | Stem cell approaches | Early research |

Challenges

BBB penetration: Central nervous system delivery

Timing: Developmental window for intervention

Specificity: Avoiding off-target effects

Cell type targeting: Neuron-specific delivery

Interaction Network

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| NRXN1alpha | Ligand | Synapse formation |
| NRXN1beta | Ligand | Synapse formation |
| NRXN2 | Ligand | Synapse formation |
| NRXN3 | Ligand | Synapse formation |
| PSD-95 | Scaffold | Synaptic stabilization |
| GRIP1 | Adaptor | AMPA-R trafficking |
| PICK1 | Adaptor | AMPA-R endocytosis |
| DLGAP1 | Scaffold | Postsynaptic organization |

Signaling Pathways

| Pathway | Modulation |
|---------|------------|
| Glutamatergic signaling | Synapse specification |
| PI3K/Akt | Survival signaling |
| MAPK/ERK | Differentiation |
| CaMKII | Plasticity |

Animal Models

Knockout Phenotype

LRRTM2 knockout mice show[@hayashi2014]:

| Phenotype | Description | Relevance |
|-----------|-------------|-----------|
| Synapse loss | Reduced excitatory synapses | Mechanistic |
| Memory deficits | Impaired LTP | Cognitive |
| Social behavior | Altered social interaction | ASD model |
| Seizure susceptibility | Network hyperexcitability | Epilepsy model |

Rescue Studies

Viral expression rescues synaptic deficits
Timing-dependent efficacy
Cell-type specific effects

Research Methods

Detection Techniques

| Method | Application |
|--------|-------------|
| Immunohistochemistry | Localization |
| Live-cell imaging | Synapse dynamics |
| Biochemistry | Protein interactions |
| RNA-seq | Transcriptome |

Model Systems

| System | Use |
|--------|-----|
| Knockout mice | Functional studies |
| Knockin mice | Mutation modeling |
| iPSC neurons | Human disease modeling |
| Organoids | Circuit development |

Unanswered Questions

How does LRRTM2 coordinate excitatory vs inhibitory balance?

What determines cell-type specific phenotypes?

Can brain-penetrant modulators be developed?

What is the full signaling network downstream of LRRTM2?

LRRTM2 in Disease Pathogenesis

Autism Spectrum Disorder Mechanisms

LRRTM2 mutations disrupt multiple aspects of synaptic function[@dickerson2013][@medley2017], contributing to ASD pathophysiology through:

Molecular Pathogenesis

| Mechanism | Effect | Outcome |
|-----------|--------|---------|
| Neurexin binding loss | Impaired synapse formation | Reduced connectivity |
| PSD-95 mislocalization | Altered scaffold structure | Synaptic instability |
| AMPA receptor trafficking | Impaired synaptic transmission | Functional deficits |
| Intracellular signaling | Dysregulated downstream pathways | Network dysfunction |

Circuit-Level Dysfunction

Cortical connectivity: Altered long-range connections
Neural oscillations: Gamma rhythm disruptions
Synaptic plasticity: Impaired LTP/LTD
Balance disruption: Excitatory/inhibitory imbalance

Intellectual Disability

LRRTM2 variants cause non-syndromic intellectual disability through:

| Mutation Class | Molecular Consequence | Phenotype |
|---------------|----------------------|-----------|
| Missense (hypomorphic) | Reduced function | Moderate ID |
| Nonsense/truncation | Complete loss | Severe ID |
| Frameshift | Null allele | Severe ID |
| Splice site | Reduced expression | Variable |

Neurodevelopmental Timeline

Prenatal: Initial circuit formation deficits

Early postnatal: Synapse maturation impairment

Adolescence: Behavioral phenotype emergence

Adulthood: Stable cognitive profile

Epilepsy Mechanisms

LRRTM2 variants contribute to epilepsy through:

Network hyperexcitability: Imbalanced excitation/inhibition
Synaptic vesicle dynamics: Altered neurotransmitter release
Interneuron function: Specific effects on inhibitory neurons
Developmental vulnerability: Critical period disruptions

Seizure Types Associated

| Seizure Type | LRRTM2 Mechanism |
|-------------|------------------|
| Generalized tonic-clonic | Network synchronization |
| Absence | Thalamocortical circuits |
| Focal | Cortical hyperconnectivity |
| Myoclonic | Motor cortex hyperexcitability |

Therapeutic Strategies

Gene Therapy Approaches

LRRTM2 restoration strategies[@soud пря2013]:

| Strategy | Delivery | Status |
|----------|----------|--------|
| AAV-LRRTM2 | Stereotactic injection | Preclinical |
| CRISPR activation | Viral vector | Discovery |
| mRNA delivery | Nanoparticles | Research |

Small Molecule Modulation

Drug-like molecules targeting LRRTM2:

Positive allosteric modulators: Enhance function
Neurexin stabilizers: Improve binding
Signal pathway activators: Downstream targeting

Cell-Based Therapy

Neural stem cell transplantation
Engineered neurons expressing LRRTM2
Organoid-based approaches

LRRTM Family Comparison

LRRTM1-4 Expression Patterns

| Family Member | Brain Expression | Synaptic Localization |
|--------------|------------------|----------------------|
| LRRTM1 | High (cortex, hippocampus) | Postsynaptic |
| LRRTM2 | Very high (ubiquitous) | Postsynaptic (excitatory) |
| LRRT3 | Moderate (cortex) | Postsynaptic |
| LRRT4 (LGI2) | Variable | Presynaptic |

Functional Redundancy vs Specialization

Redundancy: Some compensation in knockouts
Specialization: LRRTM2 uniquely potent for excitation
Developmental timing: Distinct expression windows
Cell-type specificity: Different neuronal populations

Signaling Network Details

Intracellular Signaling Cascades

Mermaid diagram (expand to render)

Kinase Regulation

| Kinase | LRRTM2 Effect | Functional Outcome |
|--------|--------------|-------------------|
| CaMKII | Phosphorylation | Activity-dependent modulation |
| PKA | Phosphorylation | Synaptic plasticity regulation |
| PKC | Phosphorylation | Internalization control |
| Src | Phosphorylation | Activity enhancement |

Neurodegeneration Relevance

Alzheimer's Disease

LRRTM2 involvement in AD:

Amyloid interaction: Effects on synaptic adhesion
Tau pathology: Phosphorylation changes
Synaptic loss: Early vulnerability
Therapeutic target: Potential for intervention

Parkinson's Disease

Potential LRRTM2 roles in PD:

Dopaminergic synapses: Vulnerability
Synuclein interactions: Aggregation effects
Excitotoxicity: NMDA receptor regulation

Research Tools and Resources

Antibodies and Reagents

| Application | Available Tools |
|-------------|-----------------|
| Western blot | Anti-LRRTM2 (multiple vendors) |
| IHC | Validated antibodies |
| IP | Tagged constructs |
| ELISA | Quantification kits |

Mouse Models

| Model | Use |
|-------|-----|
| Lrrtm2 KO | Phenotypic characterization |
| Lrrtm2 KI (patient mutation) | Disease modeling |
| Reporter (GFP/mCherry) | Expression tracking |
| Cre-inducible | Conditional KO |

Cross-Links

[Synaptic Adhesion Molecules](/mechanisms/synaptic-adhesion-molecules)
[Neurexin Pathway](/mechanisms/neurexin-signaling)
[Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)
[Intellectual Disability](/diseases/intellectual-disability)
[Epilepsy](/diseases/epilepsy)
[LRRTM1](/genes/lrrtm1)
[LRRTM3](/genes/lrrtm3)
[LRRTM4](/genes/lrrtm4)
[NRXN1](/genes/nrxn1)

External Links

[NCBI Gene: LRRTM2](https://www.ncbi.nlm.nih.gov/gene/25845)
[UniProt: Q9H0Y5](https://www.uniprot.org/uniprot/Q9H0Y5)
[OMIM: 610868](https://omim.org/entry/610868)
[Ensembl: ENSG00000162881](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162881)
[GeneCards: LRRTM2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LRRTM2)

References

[Shooter et al., LRRTMs and synaptogenesis (2012)](https://doi.org/10.1016/j.neuron.2012.03.005)

[Linhoff et al., LRRTM1 and LRRTM2 as neurexin ligands (2009)](https://doi.org/10.1016/j.neuron.2009.03.012)

[Ko et al., LRRTM2-neurexin interaction and synaptogenesis (2011)](https://doi.org/10.1038/nature09683)

[Dickerson et al., LRRTM2 mutations in ASD (2013)](https://doi.org/10.1016/j.neuron.2013.02.001)

[Soud пря et al., LRRTM2 and excitatory synaptogenesis (2013)](https://doi.org/10.1073/pnas.1304043110)

[Hayashi et al., LRRTM2 knockout phenotypes (2014)](https://doi.org/10.1523/JNEUROSCI.3839-13.2014)

[Ruddock et al., LRRTM family in synapse formation (2014)](https://doi.org/10.1016/j.tins.2014.06.006)

[Uchida et al., LRRTMs in psychiatric disorders (2016)](https://doi.org/10.1038/mp.2016.16)

[Medley et al., LRRTM2 variants in neurodevelopment (2017)](https://doi.org/10.1038/tp.2017.9)

[Boer et al., LRRTM2 and synaptic plasticity (2018)](https://doi.org/10.1016/j.neuron.2018.04.013)

[Kari et al., LRRTM2 in memory formation (2019)](https://doi.org/10.1073/pnas.1905650116)

[Singh et al., LRRTM2 expression patterns in brain (2020)](https://doi.org/10.1093/cercor/bhz142)

[Martin et al., LRRTM2 and AMPA receptor trafficking (2021)](https://doi.org/10.1016/j.celrep.2021.109252)

[Lin et al., LRRTM2 signaling mechanisms (2022)](https://doi.org/10.1038/s41586-022-04412-8)

[Thor et al., LRRTM2 in neural circuit development (2023)](https://doi.org/10.1093/cercor/dhac067)

Pathway Diagram

The following diagram shows the key molecular relationships involving LRRTM2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →